Vaccination for Dengue Prevention

Adams et al discuss the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the FDA-licensed live-attenuated dengue vaccine in the US. Dengue is caused by 4 closely related viruses (DENV-1-4) and is a growing public health concern, with an expanding range of areas w...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2022-03, Vol.327 (9), p.817-818
Main Authors: Adams, Laura E, Waterman, Steve, Paz-Bailey, Gabriela
Format: Article
Language:English
Subjects:
Children
Climatic conditions
Dengue - prevention & control
Dengue fever
Dengue Vaccines
Humans
Immunization
Public health
Vaccination
Vaccines
Vector-borne diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adams et al discuss the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the FDA-licensed live-attenuated dengue vaccine in the US. Dengue is caused by 4 closely related viruses (DENV-1-4) and is a growing public health concern, with an expanding range of areas with climate conditions conducive to the mosquito vector. In 2019, more than 3 million dengue cases were reported from countries in South, Central, and North America, which was the highest number on record. From 2010 to 2020, dengue outbreaks in endemic US territories such as Puerto Rico, US Virgin Islands, and American Samoa involved more than 30 000 reported cases, about half of which occurred among children aged 0 through 19 years. Among the 30 000 cases, there were 68 fatalities, 6 of which occurred among children.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2021.23466